VKTX - Viking Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5524.97M
Enterprise Value 3227.36M
Trailing P/E N/A
Forward P/E 1-10.54
PEG Ratio (5 yr expected) 1-0.39
Price/Sales (ttm)N/A
Price/Book (mrq)1.82
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6N/A

Trading Information

Stock Price History

Beta (3Y Monthly) 2.96
52-Week Change 3-60.49%
S&P500 52-Week Change 32.63%
52 Week High 320.85
52 Week Low 36.53
50-Day Moving Average 37.11
200-Day Moving Average 38.10

Share Statistics

Avg Vol (3 month) 31.26M
Avg Vol (10 day) 31.17M
Shares Outstanding 572.21M
Float 57.44M
% Held by Insiders 111.03%
% Held by Institutions 168.50%
Shares Short (Aug 15, 2019) 421.98M
Short Ratio (Aug 15, 2019) 415.86
Short % of Float (Aug 15, 2019) 434.17%
Short % of Shares Outstanding (Aug 15, 2019) 430.43%
Shares Short (prior month Jul 15, 2019) 422.75M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-8.77%
Return on Equity (ttm)-11.40%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA N/A
Net Income Avi to Common (ttm)-24.44M
Diluted EPS (ttm)-0.35
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)292.64M
Total Cash Per Share (mrq)4.05
Total Debt (mrq)801k
Total Debt/Equity (mrq)0.28
Current Ratio (mrq)52.19
Book Value Per Share (mrq)3.99

Cash Flow Statement

Operating Cash Flow (ttm)-17.79M
Levered Free Cash Flow (ttm)-13.24M